Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome

Katrien M.J. Devreese, Stéphane Zuily, Pier Luigi Meroni

Research output: Contribution to journalArticlepeer-review


The diagnosis of antiphospholipid syndrome (APS) relies on the detection of antiphospholipid antibodies (aPL). Currently, lupus anticoagulant (LA), anticardiolipin (aCL), and antibeta2-glycoprotein I antibodies (aβ2GPI) IgG or IgM are included as laboratory criteria, if persistently present. LAC measurement remains a complicated procedure with many pitfalls and interfered by anticoagulant therapy. Solid-phase assays for aCL and aβ2GPI show interassay differences. These methodological issues make the laboratory diagnosis of APS challenging. In the interpretation of aPL. results, antibody profiles help in identifying patients at risk. Other aPL, such as antibodies against the domain I of beta2-glycoprotein (aDI) and antiphosphatidylserine-prothrombin (aPS/PT) antibodies have been studied in the last years and may be useful in risk stratification of APS patients. Because of the methodological shortcomings of immunological and clotting assays, these non-criteria aPL may be useful in patients with incomplete antibody profiles to confirm or exclude the increased risk profile. This manuscript will focus on the laboratory aspects, the clinical relevance of assays and interpretation of aPL results in the diagnosis of APS.

Original languageEnglish
Article number100134
JournalJournal of Translational Autoimmunity
Publication statusPublished - Jan 2021


  • Anti-β2 glycoprotein I antibodies
  • Anticardiolipin antibodies
  • Antiphospholipid syndrome
  • Lupus anticoagulant
  • Non-criteria antiphospholipid antibodies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome'. Together they form a unique fingerprint.

Cite this